Loading company…
Zhejiang Dejin develops recombinant botulinum toxin products using gene engineering.
Zhejiang Dejin develops recombinant botulinum toxin injections, including DJ-01, for medical institutions and aesthetic clinics. Founded in 2023, the company is based in Hangzhou, China. In January 2026, it raised Series A funding led by HighLight Capital to advance clinical research, build an industrialization base, and expand internationally.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in